In Brief This Week: Quest Diagnostics; Thermo Fisher; DiagnoCure; TGen; Med BioGene | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an accelerated share repurchase deal with Morgan Stanley to buyback about $350 million of Quest's common stock as part of its share repurchase program. The deal is expected to complete in the fourth quarter. The company last month announced the board approved an increase to its share repurchase authorization of $1.0 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.